Stock Scorecard



Stock Summary for PTC Therapeutics Inc (PTCT) - $41.96 as of 11/20/2024 8:37:20 PM EST

Total Score

7 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PTCT

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PTCT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PTCT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PTCT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PTCT (34 out of 90)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0

Latest News for for PTCT

FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency 11/15/2024 5:49:00 AM
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain - PTC Therapeutics ( NASDAQ:PTCT ) 11/14/2024 6:46:00 PM
PTC Therapeutics ( PTCT ) Reports Q3 Loss, Tops Revenue Estimates 11/7/2024 10:25:00 PM
Unlocking Q3 Potential of PTC Therapeutics ( PTCT ) : Exploring Wall Street Estimates for Key Metrics 11/6/2024 2:15:00 PM
Analysts Estimate Stevanato Group ( STVN ) to Report a Decline in Earnings: What to Look Out for 10/22/2024 2:01:00 PM
Will PTC Therapeutics ( PTCT ) Report Negative Q3 Earnings? What You Should Know 10/17/2024 2:01:00 PM
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Larimar Therapeutics ( NASDAQ:LRMR ) 10/16/2024 6:59:00 PM
Majority of children with spinal muscular atrophy ( SMA ) treated with Roche's Evrysdi are able to sit, stand and walk independently, two-year data demonstrate 10/14/2024 5:00:00 AM
PTC Therapeutics ( PTCT ) Surges 16.5%: Is This an Indication of Further Gains? 10/9/2024 7:07:00 PM
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program 10/9/2024 5:40:00 PM

Financial Details for PTCT

Company Overview

Ticker PTCT
Company Name PTC Therapeutics Inc
Country USA
Description PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 41.96
Price 4 Years Ago 61.03
Last Day Price Updated 11/20/2024 8:37:20 PM EST
Last Day Volume 722,545
Average Daily Volume 821,144
52-Week High 46.98
52-Week Low 20.75
Last Price to 52 Week Low 102.22%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -6.75
Free Cash Flow Ratio 3.19
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.10
Total Cash Per Share 13.14
Book Value Per Share Most Recent Quarter -13.70
Price to Book Ratio 1,743.27
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 3.36
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 77,125,000
Market Capitalization 3,236,165,000
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -12.09%
Reported EPS 12 Trailing Months -5.94
Reported EPS Past Year -3.86
Reported EPS Prior Year -6.54
Net Income Twelve Trailing Months -453,201,000
Net Income Past Year -626,604,000
Net Income Prior Year -559,017,000
Quarterly Revenue Growth YOY 0.10%
5-Year Revenue Growth 25.27%
Operating Margin Twelve Trailing Months -0.26

Balance Sheet

Total Cash Most Recent Quarter 1,013,357,000
Total Cash Past Year 876,739,000
Total Cash Prior Year 410,705,000
Net Cash Position Most Recent Quarter 728,551,000
Net Cash Position Past Year -1,027,257,000
Long Term Debt Past Year 1,903,996,000
Long Term Debt Prior Year 571,722,000
Total Debt Most Recent Quarter 284,806,000
Equity to Debt Ratio Past Year -0.75
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -818,555,000
Total Stockholder Equity Prior Year -347,086,000
Total Stockholder Equity Most Recent Quarter -1,054,352,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -274,186,000
Free Cash Flow Per Share Twelve Trailing Months -3.56
Free Cash Flow Past Year -279,037,000
Free Cash Flow Prior Year -509,114,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.83
MACD Signal 1.62
20-Day Bollinger Lower Band 28.25
20-Day Bollinger Middle Band 35.91
20-Day Bollinger Upper Band 43.56
Beta 0.63
RSI 62.12
50-Day SMA 32.00
150-Day SMA 37.58
200-Day SMA 39.43

System

Modified 11/19/2024 10:47:42 AM EST